Selecta Biosciences Garners $22,000,000 Series D Funding

  • Feed Type
  • Date
    10/27/2011
  • Company Name
    Selecta Biosciences
  • Mailing Address
    480 Arsenal St. Building One Watertown, MA 02472
  • Company Description
    Selecta Biosciences, Inc. is a biopharmaceutical company developing an entirely new class of targeted vaccines that induces an antigen-specific immune activation or antigen-specific immune tolerance for therapeutic and prophylactic applications. Selecta’s proprietary Synthetic Vaccine Particle platform creates a new paradigm in vaccine development, enabling completely new therapeutic applications while offering the potential of improved efficacy and safety profiles.
  • Website
    http://www.selectabio.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $22,000,000
  • Transaction Round
    Series D
  • Proceeds Purposes
    Selecta will use the proceeds from these financings to accelerate its pipeline of products and expand the applications of its Synthetic Vaccine Particle (SVP). The company is expanding its capabilities by establishing a wholly-owned subsidiary in Moscow, Russia. The increased ability to grow Selecta’s pipeline and improved international market access provide competitive advantages for Selecta to build its business.
  • M&A Terms
  • Venture Investor
    Undisclosed

Trending on Xconomy